Novartis AG (ADR) (NVS) is Downgraded by Morgan Stanley to Underweight

Novartis AG (ADR) (NVS) was Downgraded by Morgan Stanley to ” Underweight”. Earlier the firm had a rating of “Equal-Weight ” on the company shares. Morgan Stanley advised their investors in a research report released on Apr 12, 2016.

Many Wall Street Analysts have commented on Novartis AG (ADR). Novartis AG (ADR) was Downgraded by Morgan Stanley to ” Underweight” on Apr 12, 2016. Novartis AG (ADR) was Downgraded by Leerink Partners to ” Mkt Perform” on Mar 23, 2016.

On the company’s financial health, Novartis AG (ADR) reported $1.12 EPS for the quarter, missing the analyst consensus estimate by $ -0.10 based on the information available during the earnings call on Jan 27, 2016. Analyst had a consensus of $1.22. The company had revenue of $12520.00 million for the quarter, compared to analysts expectations of $12675.19 million. The company’s revenue was down -12.8 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $1.21 EPS.

Novartis AG (ADR) closed down -0.11 points or -0.15% at $75.11 with 20,98,586 shares getting traded on Monday. Post opening the session at $75.54, the shares hit an intraday low of $75.06 and an intraday high of $75.645 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

Novartis AG is a holding company that through its subsidiaries is engaged in development manufacturing and marketing of a range of healthcare products led by pharmaceuticals around the world. Its portfolio includes medicines eye care generic pharmaceuticals preventive vaccines and over-the-counter (OTC) products. The Company’s segments include Pharmaceuticals which include patent-protected prescription medicines; Alcon which include surgical ophthalmic pharmaceutical and vision care products; Sandoz which include generic pharmaceuticals and Consumer Health which includes the OTC Division. Pharmaceuticals products include Afinitor/Votubia Exjade Galvus Exforge and Voltaren among others. Its Sandoz products include Valsartan (Diovan) Cyclophosphamide injection and AirFluSal Forspiro among others. Its OTC offers readily available consumer medicine. The Company operates Admune Therapeutics as a wholly owned subsidiary.

Novartis AG (ADR)

Leave a Reply

Novartis AG (ADR) - Is it time to Sell?

Top Brokerage Firms are advising their investors on Novartis AG (ADR). Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.